Eli Lilly and Company
已更新

LLY Eli Lilly: $555 | a look into an Outperformer

701
fundamentally sound as it addresses world problems
in the field of science medicine
it acquires great companies to grow its portfolio
and price wise lets investors get out at premium
yet provides ample time to those who are patient to accumulate during down years

impressive board
leadership is topnotch

if you missed the bottom and fomo in at the top or highs
be ready to sit on for 3 to 7 years to break even
as such an established cycle according to weather and healthcare
註釋
note/// a reminder that it pays to missout the bottom and run up
rather than be stuck for years

buying at breakouts after the consilodation stage is much better
at current levels.. WAIT
註釋
no hunting stops. decent higher lows
註釋
rise of Walking Pneumonia and that illusive Disease X
sustain this Stock upward trajectory as premier trusted in the field of science...
CONFIDENCE is mostly valued in this line of business
註釋
unstopabble and discretely acquiring disruptors or potential promising projects

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。